Assembly Biosciences (NASDAQ:ASMB) Rating Lowered to Hold at StockNews.com

Assembly Biosciences (NASDAQ:ASMB) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday.

Separately, HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a report on Monday.

Assembly Biosciences Stock Performance

Shares of Assembly Biosciences stock traded up $0.11 on Monday, hitting $11.12. The stock had a trading volume of 25,324 shares, compared to its average volume of 24,453. The stock has a 50 day moving average of $12.84 and a 200 day moving average of $15.09. The firm has a market capitalization of $70.68 million, a P/E ratio of -1.65 and a beta of 0.62. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18. The firm had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. Equities analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Michael Houghton bought 3,202 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now owns 3,202 shares of the company’s stock, valued at $49,983.22. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors have recently modified their holdings of ASMB. Gilead Sciences Inc. bought a new position in Assembly Biosciences during the fourth quarter worth $34,865,000. Peapod Lane Capital LLC acquired a new stake in Assembly Biosciences during the 4th quarter worth about $994,000. B Group Inc. acquired a new stake in Assembly Biosciences during the 4th quarter worth about $799,000. Monimus Capital Management LP acquired a new position in shares of Assembly Biosciences in the 4th quarter valued at about $664,000. Finally, Renaissance Technologies LLC boosted its position in shares of Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock valued at $1,495,000 after purchasing an additional 29,087 shares in the last quarter. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.